Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination

Division

South Atlantic

Hospital

Orange Park Medical Center

Document Type

Case Report

Publication Date

5-2022

Keywords

Pemphigoid, Bullous Pemphigoid, BP, COVID-19 vaccine adverse effects, SARS-CoV-2, COVID-19, Moderna COVID-19 mRNA vaccine, autoimmune bullous disease, anti-laminin gamma-1 (p200) pemphigoid, p200 pemphigoid

Disciplines

Dermatology | Immune System Diseases | Skin and Connective Tissue Diseases

Abstract

As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely unique, and further investigation into this pathophysiology is warranted.

Publisher or Conference

Skin: The Journal of Cutaneous Medicine

Link to Full Text

Share

COinS